Biocon
Christopher Bihari currently serves as the Head of US Sales & Commercial Strategy at Biocon, having joined the company in January 2024. Prior to this role, Bihari was the Vice President of Sales at Slayback Pharma from April 2021 to January 2024 and the National Sales Director at Glenmark Pharmaceuticals from August 2016 to April 2021. Bihari has extensive experience managing key accounts and has successfully developed relationships with major customers such as McKesson, Walmart, and various GPOs. Bihari's career also includes positions at Sandoz as Director of National Accounts, at Fougera Pharmaceuticals as National Account Executive, and at Alliant Pharmaceuticals as National Account Manager. Bihari began the professional journey at Cardinal Health as Manager of Strategic Purchasing after obtaining a BSBA in Finance and Political Science from the University of Kentucky.
This person is not in any teams
This person is not in any offices
Biocon
22 followers
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company's brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.